A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics, of VX-993

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 4, 2024

Primary Completion Date

June 12, 2024

Study Completion Date

June 12, 2024

Conditions

Pain

Interventions

DRUG

VX-993

Suspension for oral administration.

DRUG

Placebo

Suspension for oral administration.

Trial Locations (1)

ICON Salt Lake City, Salt Lake City

All Listed Sponsors

lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT06226454 - A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics, of VX-993 | Biotech Hunter | Biotech Hunter